Table 1.
Vaccines authorized for emergency use or approved for full use.
| Sr. no | Vaccine name | Manufacturer | Types of vaccine | Country of origin | Dose | Storage (°C) | Efficacy | References |
|---|---|---|---|---|---|---|---|---|
| 1. | BNT162b2 (Community) | Pfizer-BioNTech | mRNA | Germany, United States | 2 | −80 to −60 | 95% | [117] |
| 2. | mRNA-1273 | Moderna | mRNA | United States | 2 | −25 to −15 | 94.5% | [118] |
| 3. | Ad26.COV2. S | Janssen (Johnson & Johnson) | Viral vector | United States, Netherlands | 1 | 2–8 | 66.3% | [75] |
| 4. | AZD1222 (Vaxzevria) | Oxford-AstraZeneca | Viral vector | United Kingdom, Sweden | 2 | 2–8 | 81.3% | [93] |
| (Covishield) | ||||||||
| 5. | Ad5-nCov | CanSino | Viral vector | China | 1 | 2-8 | 65.28% | [120] |
| 6. | Sputnik V | Gamaleya | Viral vector | Russia | 2 | −18.5 (2 year) | 91.6% | [102] |
| 2–8 (6 month) | ||||||||
| 7. | Covaxin | Bharat Biotech | Inactivated | India | 2 | 2–8 | 80.6% | [109] |
| 8. | BBIBP-CorV | Sinopharm (Beijing) | Inactivated | China | 2 | 2–8 | 79.34% | [89,121] |
| 9. | NVX-CoV2373 | Novavax | Protein subunit | United States | 2 | 2–8 (6 month) | 96.4% | [116] |
| −20 (2 year) | ||||||||
| 10. | Inactivated (Vero Cell) | Sinopharm (Wuhan) | Inactivated | China | 2 | 2–8 | 72.51% | [69] |
| 11. | CoronaVac | Sinovac | Inactivated | China | 2 | 2–8 | 50.38% | [109] |
| 12. | CoviVac (KoviVac) | Chumakov Center | Inactivated | Russia | 2 | 2–8 | Unknown | [123] |
| 13. | QazCovid-in (QazVac) | Kazakhstan RIBSP | Inactivated | Kazakhstan | 2 | 2–8 | Unknown | [124] |
| 14. | RBD-dimer | Anhui Zhifei Longcom | Protein subunit | China | 3 | 2–8 | Unknown | [125] |
| 15. | EpiVacCorona | FBRI | Protein subunit | Russia | 2 | 2–8 | Unknown | [126] |